Autolus Therapeutics (AUTL) Receivables (2017 - 2025)

Autolus Therapeutics (AUTL) has reported Receivables for 9 consecutive years, with $24.9 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables rose 4828.66% year-over-year to $24.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.9 million (up 4828.66% YoY) and the FY2025 annual result came in at $24.9 million, up 1636.7% from the prior year.
• Receivables retreated to $24.9 million in Q4 2025 per AUTL's latest filing, from $33.5 million in the prior quarter.
• Over the last five years, Receivables for AUTL reached as high as $33.5 million in Q3 2025 and fell as low as $506000.0 in Q4 2024.
• A 5-year average of $6.5 million and a median of $1.7 million in 2022 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables plunged 78.44% — and 2025, when it soared 5508.7%.
• Year by year, Receivables stood at $655000.0 in 2021, then soared by 137.56% to $1.6 million in 2022, then plunged by 59.83% to $625000.0 in 2023, then declined by 19.04% to $506000.0 in 2024, then jumped by 4828.66% to $24.9 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $24.9 million, $33.5 million, and $27.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.